• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Reducing the Risk of Comparator Sourcing

    Clinical Data Management

    Leveraging AI/ML Analytics for Better Clinical Development Decisions

    What is a Manufacturing Ecosystem and Why are They Growing?

    Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility

    JSR Life Sciences Consolidates KBI Biopharma and Selexis SA

    Charles River, Wheeler Bio Partner to Operate RightSource Laboratory

    Cellular Origins Launches Robotic Platform for Scalable Manufacture of Advanced Therapies

    Waters Corp. Acquires Light Scattering Company Wyatt Technology
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Manufacturing Complex Peptide APIs

    How CDMOs Can Leverage Contract Terms to Facilitate Payment

    Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility

    JSR Life Sciences Consolidates KBI Biopharma and Selexis SA

    Charles River, Wheeler Bio Partner to Operate RightSource Laboratory
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Traceability & 2D Barcodes

    Complex in Complex – New Hopes for Better Drug Delivery in Topical Dosage Formulation

    Proactive Resource Group Offers DSCSA Services for Pharma Companies

    Catalent Adds New Cryogenic Capabilities at Japanese Facility

    TraceLink, PharmaLink Partner to Simplify DSCSA Compliance
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Manufacturing Complex Peptide APIs

    How CDMOs Can Leverage Contract Terms to Facilitate Payment

    Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility

    JSR Life Sciences Consolidates KBI Biopharma and Selexis SA

    Charles River, Wheeler Bio Partner to Operate RightSource Laboratory
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA 2023 Inspection Roadmap: Is “Readiness” in Your Annual Objectives?

    FDA Watch: Are You Suitably Staffed?

    FDA Watch: Is Your Supply Chain at Risk?

    FDA Watch: CDER to Launch Guidance Snapshot Pilot Program

    "3 Key Trends" with Paul Josephs
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    U.S. Pharmacopeia (USP)

    Quotient Sciences

    LOTTE BIOLOGICS

    INCOG BioPharma Services

    Syngene International Ltd.
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    U.S. Pharmacopeia (USP)

    Quotient Sciences

    LOTTE BIOLOGICS

    INCOG BioPharma Services

    Syngene International Ltd.
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Modernizing Therapeutic Cell Production

    Science-based innovation for manufacturing high quality cells challenges dogma and terminology.

    Modernizing Therapeutic Cell Production
    Courtesy of BioSpherix
    Jeff Elliott , Contributing Writer02.06.23
    Cell and gene therapies are dominating the world of drug development. With the promise of significant breakthroughs in treatment of diabetes, cancer, and congenital conditions, it is no wonder that research and development is predicted to reach $232.5 billion by 2026, up from $186 billion in 2019, according to the Evaluate Pharma report.

    With so much at stake, attention is now shifting to adopting more modern equipment and methods to consistently produce the best cells. At the core of this trend is replacing outdated legacy manufacturing techniques where cells are exposed to air, even if meticulously filtered air, and the negative consequences of that. It is a simple sounding concept.

    Since the beginning, Good Manufacturing Practices (GMP) have been based on the use of cleanrooms and isolators. However, the industry is moving toward superior alternatives that accomplish what any air environment cannot: better protection of cells from both microbial contamination and chemical toxicity, and better control of the universal critical cell process parameters—temperature, CO2 and O2. The key is closure, another simple sounding concept.

    “Without closure and separation from air, even highly filtered air, protection from microbial contamination in cleanrooms and traditional isolators is dependent on the liberal use of gaseous and liquid chemical microbial biocides. However, they are toxic to the cells too,” says Randy Yerden, a cell biologist and CEO of New York-based BioSpherix, Ltd., a designer and manufacturer of cell incubation, processing, and production systems.

    In GMP you must prove they are not harming your cells, which takes tremendous effort. Even then, it is impossible since the damage is often insidious.

    “In addition, emerging science tells us exposure to air, even short exposures, can degrade genotypic and phenotypic integrity and contribute to variability in cell populations. It causes suboptimal transients of those three critical cell process parameters,” adds Yerden. “Yet this is the norm in cleanrooms and traditional isolators.”

    If cells are produced in a more favorable environment, you get better cells, both in terms of the number and consistency of cells produced and most important their therapeutic potency. For these reasons, moving away from legacy facilities, equipment, and practices is essential for advancing cell-based therapies.

    Single Use Technology

    One only needs to read the industry news to see where it is headed. Take the popularity of pre-sterilized, single-use systems (SUS), which have exploded in use. Keeping cells aseptic inside a pre-sterilized bag, bag/tube assembly or cassette is easy. There is less cleaning and virtually no biocide needed. Add to that the productive functionality of their associated mechanical devices, including and up to full automation, and it explains why these closed SUS devices are a dominant trend in modernization.

    Some are uni-function SUS devices, designed for one step in production (e.g., cell separation). Some are multi-function SUS devices which do several steps (e.g., cell washing and dilution). Some actually do all the steps in production, and are fully automated (toti-function SUS devices). One of the most commercially successful is toti-function SUS devices designed for automated production of CAR-T cell cancer therapies. Although limited to one specific process, these are truly modern marvels.

    However, they don’t necessarily produce the best or most cells. Recent comparability studies from the NIH show surprising results (Song H, Shao L, Prochazkova M, et al 145 Comparison of CAR-T cell manufacturing platforms reveals distinct phenotypic and transcriptional profiles Journal for ImmunoTherapy of Cancer 2021). Although the exposure to air is assumed to be minimal, it is not clear how well exposures to suboptimal transients of the critical process parameters temperature, CO2, and O2 are avoided. Other variables inherent to each fixed SUS platform might also be suboptimal and significantly influence the final cell product.

    “This is the challenge with standardized live cell process automation. Whether it is one step, or a few steps, or all the steps in production, an automated process that doesn’t degrade one kind of cell may degrade others,” explains Yerden. “Automating too early in development is a risk. Only clinical trials can tell if the cell product works.

    Developers need flexibility until clinical trials prove successful, and canned automation is not usually flexible.

    “In development, only comparability studies can tell if a process change, such as automation, improves or hurts product quality. Thus uni-function SUS devices and multi-function SUS devices impose less risk because they do not automate the entire process, but then upstream and downstream steps may still be left exposed to air.”

    Despite the runaway commercial success of automated toti-function SUSs, the obvious up-front limitation is that most cell production processes do not fit in these devices.

    “Even if one does fit, will that cell product be clinically effective, or will non-obvious inherent limitations compromise the potency? Certain CAR-Ts are effective, thankfully, but the verdict is still out with other cells,” explains Yerden.

    New Category Challenges Dogma & Terminology

    Alternatives are starting to appear that achieve all the objectives: complete closure, complete avoidance of air, and virtually no limits or constraints up-front or over time. Some are difficult to describe because they do it in a different way. One example is the Xvivo System model X2 from BioSpherix.

    As Yerden explains, “Unlike closed SUS devices, the X2 modular closed system is not constrained to any particular process but can accommodate any entire cell production process - large or small, simple or complex, centralized or distributed, manual or automated.

    With interconnected glove chambers, from the outside it looks like an isolator. However, looks don’t tell the whole story. Isolator dogma brings with it preconceived notions: HVAC connections, filtered air blowing through, thick heavy gloves, etc. Like a modern automobile, you really have to look under the hood to find out if it is old gas or new electric.

    The Xvivo System is infinitely configurable with unprecedented plug and play modularity. It assembles from a comprehensive library of modular chambers, co-chambers, and sub-chambers, interconnecting in all different ways to efficiently close by form and fit around the workflow of any different entire production process, including all analytic, processing, and automation equipment.

    Cell production often consists of many widely diverse steps. Technicians or industrial robotic arms use the gloves from the outside for manual or man-mimetic robotic steps, or for tending to the equipment or automation inside.

    However, in the context of producing high quality cells by avoiding contamination and toxic chemicals, it is more comparable to SUSs.

    “It is not a SUS of any kind, but like a SUS it makes aseptic cell production easy,” says Yerden. “Instead of ease with pre-sterilized disposables, it self-sanitizes the entire internal production environment automatically without risky biocides. No biocides may sound like heresy according to GMP dogma, but it works, and the data trumps the dogma. In this regard it could also be called a next generation isolator, or Cytocentric isolator.”

    Instead of air inside, it is filled with a mix of pure N2, O2 and CO2 gases from tanks. CO2 and O2 can be controlled at optimal levels for cells throughout the system, just like an incubator or bioreactor. Temperature can also be controlled, just like an incubator or bioreactor.

    “By eliminating the fluctuations and transient exposures to suboptimal temperature, CO2 and O2 usually caused by all the typical exposures to air in cleanrooms or traditional isolators, you always get cells with better consistency and quality. Sometimes radically better,” emphasizes Yerden.

    Notably most stem cells and primary cultures fresh from the patient do best at low O2 levels, which simulate normal physiologic levels. In fact, it is the only cell manufacturing platform that can optimize this critical parameter at every step of production, simultaneously with physiologic CO2 and temperature. However, where necessary, you can simulate air without air, inert with 100% nitrogen, or chill down to refrigerator temperatures.

    Compared to cleanrooms, it reduces facility costs by 90% when you look at total cost of ownership at equivalent production capacity over the facility lifecycle. Extremely low operating cost is the game changer, although many forget to factor that into future facility cost estimates.

    “When you do, it brings cGMP cell production within reach of even the smallest companies. Combine that with the speed and flexibility of deployment, multi-modal capability due to closure, easy path to regulatory approval due to closure, reduction in virtually all the risks, and high quality of the live cell products, it is next generation regardless of what you call it,” concludes Yerden. 


    Jeff Elliott is a Torrance, Calif.-based technical writer. He has researched and written about industrial technologies and issues for the past 20 years.
    Related Searches
    • Biologics, Proteins, Vaccines
      Loading, Please Wait..
      Trending
      • Aurigene Expands Biologics CDMO Capacity
      • Astellas To Transfer Manufacturing Plant To Delpharm
      • Catalent Adds New Cryogenic Capabilities At Japanese Facility
      • Thermo Fisher Expands Steriles Facility In Asia-Pacific Region
      • Lifecore Biomedical Enters Into $150M New Financing Deal
      Breaking News
      • Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility
      • JSR Life Sciences Consolidates KBI Biopharma and Selexis SA
      • Charles River, Wheeler Bio Partner to Operate RightSource Laboratory
      • Cellular Origins Launches Robotic Platform for Scalable Manufacture of Advanced Therapies
      • Waters Corp. Acquires Light Scattering Company Wyatt Technology
      View Breaking News >
      CURRENT ISSUE

      May 2023

      • New Modalities Hog the Limelight
      • Cell and Gene Therapy is Coming of Age
      • Demand Surges for Cell and Gene Therapy Contract Manufacturing
      • Embracing a New Reality
      • Japan: A Unique Opportunity for Regenerative Medicines and Cell & Gene Therapies
      • Single-Use Technologies Enable Biologic Scaling
      • Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
      • FTEs in Drug Discovery
      • Digital Transformation in Pharma
      • What is a Manufacturing Ecosystem and Why are They Growing?
      • View More >

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Verdure Sciences Receives Award for Sustainable, Ethical Turmeric Sourcing
      BGG Receives Patent for Saw Palmetto ID Method
      Premium Label & Packaging Solutions Receives Safe Quality Food (SQF) Certification
      Coatings World

      Latest Breaking News From Coatings World

      Brand Finance: Post-COVID Recovery Slows for Chemicals Industry Battling Energy Crisis
      BCF Calls for Greater Urgency on REACH Impasse
      MNYCA Hosts Afternoon Baseball Event
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      CareDx, Miromatrix Collaborate on Bioengineered Organs Research
      Capitainer Releases to Market its Fully Automated Sample Handler
      Titan Medical Licenses Most IP to Intuitive; CEO Steps Down
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility
      JSR Life Sciences Consolidates KBI Biopharma and Selexis SA
      Charles River, Wheeler Bio Partner to Operate RightSource Laboratory
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Stetson Introduces Men’s Grooming Portfolio
      Two Executives Depart from Unilever Amid CEO Transition
      L’Oréal Paris Welcomes Thuso Mbedu as Brand Ambassador
      Happi

      Latest Breaking News From Happi

      Beautycounter Appoints Board Director Mindy Mackenzie Interim CEO
      Unilever Ventures’ Backs Selva Ventures in $34 Million Fund for Early-Stage CPG Brands
      Two Executives Depart from Unilever Amid CEO Transition
      Ink World

      Latest Breaking News From Ink World

      ACTEGA, Makro Labelling to Advance Signite Technology
      BCF Requests Greater Urgency on REACH Impasse
      Updated Method Published for Entire BASF Product Portfolio
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      ACTEGA teams with Makro Labelling to advance Signite technology
      Constantia Flexibles and SB Packagings commence joint venture
      Inland donates new VersaStudio printer to local high school
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Mann+Hummel Names President Air Filtration Americas
      KNH Launches Eco-Friendly Menstrual Pads
      Niine Introduces India's First PLA-Based Sanitary Pads
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Enrollment Completed in Anika Therapeutics' Hyalofast Study
      Exactech Releases Next-Gen GPS Shoulder
      Data Shows Favorable Survivorship of MISHA Knee System & Reduction of Arthroplasty Risk in Patients
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      onsemi Presents Path to Accelerate Revenue Growth
      STMicroelectronics Introduces Waterproof MEMS Pressure Sensor
      Graphene Flagship to Join Euro Nano Forum 2023

      Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login